A problematic pattern of using benzodiazepines, sleep medications, or similar sedating drugs, often beginning with a legitimate prescription.
Medically reviewed by
Dr. Mihaela G.
Sedative, Hypnotic, or Anxiolytic Use Disorder describes a problematic pattern of using benzodiazepines (such as alprazolam, lorazepam, or diazepam), sleep medications, barbiturates, and related sedating substances, leading to clinically significant impairment or distress. This category occupies an unusual clinical position: unlike most substances in this chapter, these medications are legitimately prescribed, extremely commonly used, and genuinely effective for the conditions they treat, anxiety, insomnia, certain seizure disorders, making the line between appropriate medical use and a developing use disorder a particularly important and sometimes genuinely subtle one to recognize.
This is also the substance category most closely related to alcohol in its underlying mechanism, since both act primarily through the GABA neurotransmitter system, and this shared mechanism has real clinical significance: combining sedatives with alcohol or opioids significantly compounds respiratory depression risk, and the withdrawal syndrome, much like alcohol withdrawal, can be genuinely medically dangerous, including risk of seizures, making unsupervised discontinuation after sustained use a serious safety concern rather than simply an uncomfortable process to push through.
A particularly important distinction within this category is between physical dependence developing under appropriate, ongoing medical supervision and the broader pattern of impaired control, craving, and continued use despite harm that defines an actual use disorder; many people taking these medications exactly as prescribed develop physical dependence without developing the disorder itself.
Impaired control over use
Using more or for longer than intended, persistent desire or unsuccessful efforts to cut down, and spending significant time obtaining, using, or recovering from use.
Social and functional impairment
Continued use despite interpersonal or occupational problems, giving up important activities, and recurrent use in physically hazardous situations, particularly given how significantly these substances impair coordination and alertness.
Risky use and craving
Continued use despite knowledge of physical or psychological harm, and persistent craving.
Tolerance
Needing markedly increased amounts for the same effect, often developing gradually enough that a person may not immediately recognize how much their usage has escalated over time.
Withdrawal
A potentially medically serious withdrawal syndrome when use is reduced or stopped after sustained use, sharing important similarities with alcohol withdrawal given the shared underlying mechanism.
⋅ Significant anxiety, particularly anticipatory anxiety about running out of medication
⋅ Craving and a strong urge to use
⋅ Emotional blunting connected to sustained, heavy use
⋅ Irritability when use is interrupted or reduced
⋅ Persistent preoccupation with obtaining or maintaining adequate supply
⋅ Memory impairment, particularly affecting new learning during periods of use
⋅ Minimization of the extent of use, particularly given the medication’s legitimate medical purpose
⋅ Difficulty concentrating, both during use and during withdrawal
⋅ Tolerance, requiring increasing doses for the same effect
⋅ Sedation, drowsiness, and impaired coordination
⋅ Significant physical withdrawal symptoms when use is reduced or stopped after sustained use
⋅ Impaired balance and increased fall risk, particularly relevant in older adults
⋅ Using more or for longer than directed on a recurrent basis
⋅ Seeking multiple prescriptions or sources to maintain supply
⋅ Continued use despite clear cognitive, occupational, or safety consequences
⋅ Combining with alcohol or other sedating substances despite known risk
This disorder has a 12-month prevalence of approximately 0.2%, though rates are considerably higher among people with long-term benzodiazepine prescriptions, reflecting how the disorder frequently develops within, rather than entirely outside of, a legitimate medical treatment context.
Risk factors include long-term prescription use beyond generally recommended treatment durations, a personal or family history of other substance use disorders, co-occurring anxiety or sleep disorders, and, notably, older age, given how commonly these medications are prescribed for sleep and anxiety in older adults, alongside increased sensitivity to their effects and associated fall risk in this population.
Comorbidity with anxiety disorders, insomnia, and other substance use disorders, particularly alcohol and opioids, is substantial, and the combination with opioids specifically carries serious, well-documented overdose risk through compounded respiratory depression.
This disorder develops through an interaction of neurobiological, prescribing-pattern, and individual factors, closely paralleling the mechanisms underlying alcohol use disorder given the shared neurotransmitter system involved.
GABA system enhancement and adaptation is central to the underlying mechanism; these substances enhance GABA, the brain’s primary inhibitory neurotransmitter, producing their calming, anti-anxiety, and sedating effects, while sustained use leads to compensatory neuroadaptation, reduced GABA receptor sensitivity, that underlies both tolerance and the withdrawal syndrome that follows discontinuation.
Extended duration of use beyond recommended guidelines is a particularly significant risk factor; these medications, especially benzodiazepines, are generally recommended for relatively short-term use for most indications, but real-world prescribing sometimes extends considerably longer, increasing the risk of dependence developing even within an ostensibly appropriate medical context.
Co-occurring anxiety or sleep disorders represent both a legitimate reason for initial prescribing and a meaningful risk factor for developing a use disorder, since the underlying condition being treated can create a stronger pull toward continued or escalating use, particularly if the underlying condition isn’t otherwise being adequately addressed.
Genetic and individual factors, including those affecting metabolism of these substances and overall vulnerability to substance use disorders more broadly, contribute to individual risk.
This disorder is diagnosed based on a problematic pattern of use leading to clinically significant impairment or distress, evidenced by at least two of eleven criteria within a 12-month period, following the structure used across substance use disorders: using more or longer than intended, persistent desire or unsuccessful efforts to cut down, significant time spent obtaining/using/recovering, craving, recurrent failure to fulfill role obligations, continued use despite interpersonal problems, giving up important activities, recurrent hazardous use, continued use despite physical/psychological problems, tolerance, and withdrawal. Severity is specified as mild (2-3 criteria), moderate (4-5), or severe (6 or more). As with opioids, tolerance and withdrawal aren’t counted when these substances are used solely as prescribed under appropriate medical supervision.
Differential diagnosis requires distinguishing this disorder from physical dependence occurring under appropriate, ongoing medical supervision, which doesn’t by itself constitute a use disorder, from the broader pattern of impaired control and continued use despite harm. Given how gradually escalation can occur within a legitimate prescription context, careful, ongoing clinical assessment over time, rather than a single evaluation, is often important for accurate recognition.
Treatment for this disorder requires particular care given the genuine medical risk of unsupervised discontinuation after sustained use.
Gradual, medically supervised tapering
Slow, carefully managed dose reduction, generally over a period of weeks to months depending on the duration and dose of prior use, is the cornerstone of safe treatment, given the risk of significant, potentially dangerous withdrawal, including seizures, with abrupt discontinuation after sustained use.
Cognitive-behavioral therapy
CBT, particularly when combined with tapering, has solid evidence for supporting successful discontinuation, addressing both the underlying anxiety or sleep difficulty the medication may have been treating and the psychological aspects of dependence itself.
Addressing the underlying condition
Given that many people began using these medications for legitimate anxiety or sleep difficulties, directly addressing these underlying conditions, often through therapy or alternative treatment approaches, is an important parallel component, both to support successful tapering and to address the need the medication was originally meeting.
Avoiding abrupt discontinuation
Stopping suddenly after sustained, heavy use is genuinely dangerous and should be avoided; this is one of the more medically serious withdrawal syndromes in this manual, and treatment should always proceed through careful, gradual tapering rather than abrupt cessation.
Addressing comorbid substance use
Given meaningful overlap with alcohol and opioid use, comprehensive assessment and, where needed, integrated treatment addressing all relevant substances together supports safer, more effective care.
Never stop these medications abruptly after sustained use without medical guidance. This is the single most important safety information in this entry; unsupervised, sudden discontinuation can be genuinely dangerous, including risk of seizures.
Work with your prescriber on a gradual tapering plan if you’re using more than intended or want to reduce your use. A slow, structured taper is both safer and considerably more comfortable than attempting to stop quickly.
Address the underlying anxiety or sleep difficulty directly, alongside any tapering process. Since these medications were often started for a genuine reason, working on the underlying condition, through therapy or other approaches, supports a more sustainable transition.
Be cautious about combining these medications with alcohol or opioids. This significantly increases the risk of dangerous respiratory depression, even at doses that might feel manageable for either substance alone.
If you’re an older adult using these medications regularly, discuss fall risk and cognitive effects with your physician. Sensitivity to these substances tends to increase with age, and this is worth factoring into ongoing treatment decisions.
The prognosis for this disorder with appropriate, carefully managed treatment is generally good, and gradual tapering combined with therapy supports successful discontinuation or meaningful dose reduction for many people.
Without appropriate medical guidance, particularly attempts at abrupt discontinuation, the course carries genuine medical risk, and unmanaged withdrawal can be a serious, even life-threatening, medical event.
Addressing the underlying anxiety or sleep condition that often initially prompted use is an important factor in long-term success, since unaddressed underlying symptoms can otherwise complicate sustained reduction or discontinuation.
Comorbid alcohol or opioid use, when present, requires coordinated, comprehensive treatment for the safest, most effective outcomes.
Seek evaluation if your use of these medications, or someone else’s, has escalated beyond what was prescribed or intended, or is causing problems with daily functioning.
Seek medical guidance before reducing or stopping these medications after sustained use, rather than doing so abruptly on your own. Given the genuine risk of dangerous withdrawal, a supervised, gradual approach is essential.
Seek immediate medical attention if you or someone else experiences seizures, severe confusion, or significant autonomic instability after stopping or significantly reducing use. This requires urgent evaluation and treatment.
Someone in your life might be quietly looking for this. Share it:
These conditions share overlapping symptoms and are often misdiagnosed.
Yes, physical dependence can develop even with appropriate, medically supervised use, particularly with longer-term use. This physical dependence alone doesn’t necessarily constitute a use disorder, which requires a broader pattern of impaired control and continued use despite harm. However, it does mean that stopping these medications, even when taken correctly, should generally be done through gradual tapering rather than abrupt discontinuation.
Benzodiazepines and related sedatives work through the same GABA neurotransmitter system as alcohol, and withdrawal after sustained use can produce a similarly serious syndrome, including risk of seizures. This is part of why unsupervised, abrupt discontinuation after regular, sustained use is genuinely dangerous, and why a gradual, medically supervised tapering approach is essential for safe discontinuation.
No, this combination is genuinely risky. Both substances depress the central nervous system through related mechanisms, and combining them significantly increases the risk of dangerous respiratory depression, even at doses that might feel manageable for either substance taken alone. This combination should generally be avoided.
Treatment centers on gradual, medically supervised tapering, generally over weeks to months depending on the duration and dose of prior use, combined with cognitive-behavioral therapy addressing both the dependence itself and any underlying anxiety or sleep difficulty the medication was originally treating. Abrupt discontinuation should always be avoided given the genuine medical risk involved.
Brett, J., & Murnion, B. (2015). Management of benzodiazepine misuse and dependence. Australian Prescriber, 38(5), 152–155. PubMed
Lader, M. (2011). Benzodiazepines revisited—will we ever learn? Addiction, 106(12), 2086–2109. PubMed
Soyka, M. (2017). Treatment of benzodiazepine dependence. New England Journal of Medicine, 376(12), 1147–1157. PubMed
Ait-Daoud, N., Hamby, A. S., Sharma, S., & Blevins, D. (2018). A review of alprazolam use, misuse, and withdrawal. Journal of Addiction Medicine, 12(1), 4–10. PubMed
Markota, M., Rummans, T. A., Bostwick, J. M., & Lapid, M. I. (2016). Benzodiazepine use in older adults: dangers, management, and alternative therapies. Mayo Clinic Proceedings, 91(11), 1632–1639. PubMed
